Duvelisib
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Explore 105 assets in Relapsed/Refractory Diffuse Large B-Cell Lymphoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Emory University
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04890236CT.gov Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | — | Completed | — | — | — |
NCT03892044CT.gov Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Duvelisib (this asset) | Emory University | P1 | CCC · 48 |
| Selinexor | Chengdu Zenitar Biomedical Technology Co., Ltd | P3 | BB |
| Dexasone | City of Hope Medical Center | P2/3 | BB |
| Isocyclophosphamide | University of California, Davis | P3 | BB |
| Etoposide | University of California, Davis | P3 | BB |
| Axicabtagene Ciloleucel | Zhujiang Hospital | P3 | BB |
| Cyclophosphamide | Nathan Denlinger | P3 | BB |
| Carboplatin | University of California, Davis | P3 | BB |
| Prednisone | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort
Other indications for Duvelisib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | B · 60 |
| Follicular Lymphoma | — | P3 | B · 56 |
| Indolent B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Duvelisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/duvelisib-relapsedrefractory-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →